抗人uPA/PLAU(B chain)鼠单抗
产品名称: 抗人uPA/PLAU(B chain)鼠单抗
英文名称: uPA/PLAU uPA PLAU
产品编号: 10815-MM01
产品价格: null
产品产地: 北京
品牌商标: 义翘神州(SinoBiologi
更新时间: null
使用范围: western blot
- 联系人 :
- 地址 : 北京亦庄东区科创十街18号院9号楼306室
- 邮编 : 100176
- 所在区域 : 北京
- 电话 : 点击查看
- 传真 : 点击查看
- 邮箱 : marketing@sinobiological.cn
官方网址:http://www.sinobiological.cn/Urokinase-PLAU-Antibody-g-1712.html
Urokinase-type Plasminogen Activator ( uPA / PLAU ) Antibody
Order or Inquire for uPA Antibody product | |||
Detect B chain and full-length of uPA in WB | |||
Detection limit is 25 ng/lane in WB |
uPA / PLAU抗体产品信息
免疫原 : | Recombinant human uPA protein ( Catalog#10815-H08H ) |
抗体类型: | Mouse Monoclonal Antibody ( Mouse mAb Service Platform ) |
克隆号 : | 2G11A6E10 |
抗体宿主 : | Mouse IgG1 |
缓冲液 : | 0.2 μm filtered solution in PBS with 5% trehalose |
制备方法 : | This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, human cell-derived, recombinant human uPA / PLAU ( rhPLAU; Catalog#10815-H08H; Met 1-Leu 431; NP_002649.1). The IgG fraction of the cell culture supernatant was purified by Protein A affinity chromatography. |
uPA / PLAU抗体使用指南
特异性 : | Human uPA / PLAU |
No cross-reactivity with human cell lysate ( 293 cell line ) in WB and ELISA. | |
Western blot : | This antibody can be used at 1 - 2 μg/mL with the appropriate secondary reagents to detect B chain and full-length of uPA in WB. Using a DAB detection system, the detection limit for uPA is approximately 25 ng/lane under non-reducing conditions. Use of this antibody under reducing conditions is not recommended. |
储存方法 : | This antibody can be stored at 2℃-8℃ for 1 month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -70℃. Preservative-Free. Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. Avoid repeated freeze-thaw cycles. |
uPA / PLAU Antibody Related Products & Topics
相关研究领域:
Enzyme>>Protease & Regulator>>Serine Protease & Regulator>>Urokinase/PLAU/u-PA
Cancer>>Cancer Biomarkers>>Urokinase/PLAU/u-PA
Immunology>>Innate Immunity>>Coagulation>>Urokinase/PLAU/u-PA
蛋白:
Molecule | Species | Description //For Detailed Info.------CLICK! | Cat No |
Urokinase/PLAU/u-PA | Human | Urokinase/PLAU/u-PA Protein, Recombinant | 10815-H08H |
抗体:
Molecule | Application | Description //For Detailed Info.------CLICK! | Cat No |
Human Urokinase/PLAU/u-PA | WB | Mouse Monoclonal Antibody | 10815-MM01 |
Human Urokinase/PLAU/u-PA | WB | Mouse Monoclonal Antibody | 10815-MM02 |
Human Urokinase/PLAU/u-PA | ELISA | Mouse Monoclonal Antibody | 10815-MM03 |
uPA / PLAU抗体背景综述
Plasminogen activator, urokinase, also known as PLAU and uPA, is a serine protease involved in degradation of the extracellular matrix and possibly tumor cell migration and proliferation. The human PLAU is initially synthesized as 431 amino acid precursor with a N-terminal signal peptide (20 residues). The single chain molecule is processed into a disulfide-linked two-chain molecule of different molecular weights. Two forms of the A chain exist, starting at Ser21 (the long form) and Lys156 (the short form). The long and short A chains are unique to the high and low molecular weight forms, respectively. The long A chain contains an EGF-like domain, responsible for binding of the PLAU receptor. The B chain corresponds to the catalytic domain. PLAU is a potent marker of invasion and metastasis in a variety of human cancers associated with breast, stomach, colon, bladder, ovary, brain and endometrium. A specific polymorphism in PLAU gene is implicated in late-onset Alzheimer disease and also with decreased affinity for fibrin-binding.
参考文献
- Nagai, M. et al., 1985, Gene. 36:183-8.
- Jacobs, P. et al., 1985, DNA. 4:139-46.
- Geiger, M. et al., 1989, Blood. 74 (2): 722-8.
- Ploug, M. et al., 2002, Biochem. Soc. Trans. 30 (2): 177-83.
- Duffy, MJ., 2002, Biochem. Soc. Trans. 30: 207-10.
- Alfano, M. et al., 2004, J. Leukoc. Biol. 74 (5): 750-6.